LB Pharmaceuticals Inc (LBRX)
NasdaqGM · USD · Healthcare · Biotechnology
$39.34 (+1.58%) as of
Key statistics
- Market cap
- 1.27B
- P/E (TTM)
- 393.40
- Forward P/E
- -7.67
- EPS (TTM)
- 0.10
- Dividend yield
- 0.00%
- 52-week range
- 14.32 – 50.16
- Profit margin
- 0.00%
- Analyst target
- $58.00
- Volume
- 275.98k
About LB Pharmaceuticals Inc
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New York, NY, United States
- Employees
- 49
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.